- •We assessed FH patients using PCSK9 inhibitors in a clinical setting.
- •LDL-c decrease of PCSK9 inhibitors was comparable to clinical trials.
- •However, our patients showed more side effects compared with clinical trials.
- •This emphasizes the need to monitor the long-term side effects of PCSK9 inhibitors.
Despite optimal lipid-lowering therapy, a minority of patients with familial hypercholesterolemia (FH) reach low-density lipoprotein cholesterol (LDL-c) target goals. In randomized trials, proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors led to impressive LDL-c reductions and a favorable safety profile. However, data about the efficacy and safety outside clinical trials are not available yet.
The purpose of the study is to describe efficacy and side effects of PCSK9 inhibitors in FH patients in clinical practice.
Registry of all consecutive FH patients who started with a PCSK9 inhibitor at a lipid clinic of a university hospital.
We analyzed 83 FH patients (79 heterozygous FH [heFH]—65 with a genetically confirmed heFH and 14 with clinical heFH—and 4 homozygous FH [hoFH]), with a mean age of 55.1 ± 11.6 years. Treatment with a PCSK9 inhibitor resulted in an additional reduction of 55% ± 21% in mean LDL-c levels. Patients with heFH had more LDL-c decrease than those with hoFH (56% vs 38%). Patients using ezetimibe monotherapy because of statin intolerance (n = 24, 29%) had less LDL-c decrease compared with patients who concurrently used statin therapy (47% and 58%, P = .03). Side effects of PCSK9 inhibitors were reported by 32 patients (39%). Flu-like symptoms (n = 12) and injection site reactions (n = 11) were most frequent. Seven patients (8%) discontinued treatment, 5 because of side effects and 2 because of nonresponse.
Our initial experience of PCSK9 inhibition in FH patients in a clinical setting showed comparable reduction in LDL-c levels but more side effects compared with clinical trials.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Clinical Lipidology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- A receptor-mediated pathway for cholesterol homeostasis.Science. 1986; 232: 34-47
- Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.Eur Heart J. 2015; 36: 560-565
- Familial hypercholesterolemia and coronary heart disease: a HuGE association review.Am J Epidemiol. 2004; 160: 421-429
- Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia.Circulation. 1974; 49: 476-488
- The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients.J Intern Med. 2004; 256: 482-490
- Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.Lancet. 2001; 357: 577-581
- Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.Br Med J. 2008; 337: a2423
- Ezetimibe added to statin therapy after acute coronary syndromes.N Engl J Med. 2015; 372: 2387-2397
- Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.Circulation. 2015; 132: 1224-1233
- Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in the Netherlands.Atherosclerosis. 2010; 209: 189-194
- Predicting non-adherence in patients with familial hypercholesterolemia.Eur J Clin Pharmacol. 2014; 70: 391-397
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.Lancet. 2010; 376: 1670-1681
- Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.Cardiovasc Drugs Ther. 2014; 28: 281-289
- Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dL or higher.Cardiovasc Drugs Ther. 2016; 30: 473-483
- Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.N Engl J Med. 2015; 372: 1500-1509
- Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.Eur Heart J. 2014; 35: 2249-2259
- Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation.Int J Cardiol. 2014; 171: 309-325
- Diagnosis and treatment of familial hypercholesterolaemia.Eur Heart J. 2013; 34: 962-971
- Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.Eur Heart J. 2015; 36: 1012-1022
- GVS rapport. Farmaco-Economisch rapport voor evolocumab (Repatha®) bij de behandeling van hypercholesterolemie.2015: 1-111 (Available at: https://www.zorginstituutnederland.nl/publicaties/rapport/2015/12/14/evolocumab-repatha-bij-hypercholesterolemie-en-gemengde-dyslipidemiehomozygote-familiaire-hypercholesterolemie)
- ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).Atherosclerosis. 2011; 217: 3-46
- Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents.Eur Heart J. 2016; 37: 1373-1379
- 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).Eur Heart J. 2007; 28: 1462-1536
- Diagnosis and classification of diabetes mellitus.Diabetes Care. 2010; 33 Suppl 1: S62-9
- Risk of fatal coronary heart disease in familial hypercholesterolaemia.BMJ. 1991; 303: 893-896
- Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial.Circulation. 2012; 126: 2408-2417
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.Lancet. 2015; 385: 331-340
- ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.Eur Heart J. 2015; 36: 2996-3003
- Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.J Am Coll Cardiol. 2014; 63: 2541-2548
- Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial.JAMA. 2016; 315: 1580-1590
- Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial.J Clin Lipidol. 2015; 9: 758-769
- Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study.Circ Res. 2015; 117: 731-741
- The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.Eur Heart J. 2016; 37: 536-545
Amgen. Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study Landmark Repatha Cardiovasc Outcomes Study Meets Prim Key Secondary Endpoint. THOUSAND OAKS, calif. 2017.
- Effect of evolocumab on progression of coronary disease in statin-treated patients.JAMA. 2016; 316: 2373-2384
Published online: March 07, 2017
Accepted: February 26, 2017
Received: December 28, 2016
© 2017 National Lipid Association. All rights reserved.